Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Debt-to-Equity : 0.25 (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals Debt-to-Equity?

Aurinia Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $14.7 Mil. Aurinia Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $73.8 Mil. Aurinia Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $359.5 Mil. Aurinia Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aurinia Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

AUPH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.26
Current: 0.25

During the past 13 years, the highest Debt-to-Equity Ratio of Aurinia Pharmaceuticals was 0.26. The lowest was 0.00. And the median was 0.02.

AUPH's Debt-to-Equity is ranked worse than
60.8% of 1074 companies
in the Biotechnology industry
Industry Median: 0.145 vs AUPH: 0.25

Aurinia Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Aurinia Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Debt-to-Equity Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.26

Aurinia Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.26	0.24	0.26	0.25

Competitive Comparison of Aurinia Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurinia Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Debt-to-Equity falls into.

Aurinia Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aurinia Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(15.598	+	82.009)	/	377.954
	=	0.26

Aurinia Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(14.723	+	73.814)	/	359.476
	=	0.25

Aurinia Pharmaceuticals (NAS:AUPH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aurinia Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

IKAP:Germany IKAP:Germany

Address

4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Executives

Robert T Foster	director	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
R. Hector Mackay-dunn	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w.	director	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Jill Leversage	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Daniel Billen	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Joseph P Hagan	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Brinda Balakrishnan	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Peter Greenleaf	director, officer: Chief Executive Officer	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Joseph M Miller	officer: Chief Financial Officer	C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Stephen P. Robertson	officer: EVP, General Counsel	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Milne George M Jr	director
Matthew Maxwell Donley	officer: Ex VP, Intern'l Operations	4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Scott Michael Habig	officer: Chief Commercial Officer	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8